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Abstract
Background: Physical activity (PA) is associated with disease severity in idiopathic pulmonary fibrosis (IPF), but
longitudinal studies evaluating its prognostic value and changes over time are lacking.
Methods: We measured PA (steps per day, SPD) in a cohort of 46 IPF-patients (mean age, 67 years; mean FVC, 76.
1%pred.) by accelerometry at baseline, recorded survival status during 3 years follow-up and repeated measurements
in survivors. We compared the prognostic value of PA to established mortality predictors including lung function
(FVC, DLCO) and 6-min walking-distance (6MWD).
Results: During follow-up (median 34 months) 20 patients (43%) died. SPD and FVC best identified non-survivors
(AUROC-curve 0.79, p < 0.01). After adjustment for confounders (sex, age, therapy), a standardized increase (i.e. one SD)
in SPD, FVC%pred. or DLCO%pred. was associated with a more than halved risk of death (HR < 0.50; p < 0.01).
Compared to baseline, SPD, FVC, and 6MWD annually declined in survivors by 973 SPD, 130 ml and 9 m, resulting in
relative declines of 48.3% (p < 0.001), 13.3% (p < 0.001) and 7.8% (p = 0.055), respectively.
Conclusion: While PA predicts mortality of IPF patients similar to established functional measures, longitudinal decline
of PA seems to be disproportionally large. Our data suggest that the clinical impact of disease progression could be
underestimated by established functional measures.
Keywords: Functional status (activity levels), Physical exercise, Triaxial accelerometer, Mortality, Longitudinal studies,
Idiopathic pulmonary fibrosis
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive fibros-
ing interstitial pneumonia with poor prognosis [1]. Despite
successful development of new therapies, survival has not
been convincingly improved [1–3]. Identification of vali-
dated predictors of disease progression and mortality in
IPF is essentially important for decision making in clinical
practice. Established mortality predictors have been de-
rived from large cohorts of IPF patients, and fundamental
baseline characteristics such as gender, age, lung function,
exercise capacity, and comorbidities have demonstrated
significant potential [4–12].
Lung function decline is frequently chosen as outcome
measure in clinical trials, serving as a marker for disease
progression and mortality [2, 3]. However, validity and
clinical meaning of this measure is controversial [13–18].
A recent expert working group report suggested that
besides primary survival analyses, the best evidence of the
clinical efficacy of a treatment might be derived from
direct measures of a patient’s symptoms and daily func-
tions [13]. Therefore, measures of daily physical activity
(PA) might represent a clinically meaningful surrogate
of a patient’s well-being and everyday functional status
[13, 19]. Indeed, close relationships can be shown
between PA and patient-reported outcomes, such as
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dyspnea, fatigue, and health status in patients with IPF
[20]. However, to the best of our knowledge there are
currently no studies available that have measured PA in
IPF longitudinally. Mortality and objectively measured
physical activity have previously shown some associa-
tions in patients with various entities of fibrotic idio-
pathic interstitial pneumonia [21], but data on patients
with established IPF are lacking. Furthermore, there is
no detailed analysis available comparing the prognostic
value of physical activity to established clinical indica-
tors of disease severity and progression, such as lung
function and exercise capacity.
In our study, we aimed to investigate (1) the pre-
dictive value of physical activity for all-cause mortality
and (2) the amount of physical activity decline in a
prospective longitudinal cohort of patients with IPF at
two tertiary centers for Interstitial Lung Diseases in
Germany.
Methods
Study population
In 2013, we included 48 patients with IPF (36 men, 12
women) in this prospective observational cohort and per-
formed follow-up visits between June 2016 and October
2016. All visits took place at the Pulmonary Research
Institute at LungenClinic Grosshansdorf, Grosshansdorf,
Germany, and at the Center for Interstitial and Rare Lung
Diseases, Thoraxklinik, University Heidelberg, Heidelberg,
Germany. Cross-sectional analyses at baseline and detailed
methods have been published previously [20]. Briefly,
study participants were initially recruited in the out-
patient departments of LungenClinic Grosshansdorf,
and Thoraxklinik Heidelberg, respectively, and diagno-
sis of IPF at each center was established in an interdis-
ciplinary discussion (Interstitial Lung Disease Board),
according to current guidelines [1].
We contacted the patients 3 years after the baseline
visit by telephone and invited them for a follow-up visit
at the study centers. Exact dates of death from deceased
patients were obtained from institutional databases, rela-
tives or treating physicians. Follow-up visits in survivors
followed the same protocol as the baseline visits regard-
ing the assessment of lung function, exercise capacity,
physical activity, and medical history. Two patients were
too ill to attend the outpatient departments. In these
two cases we performed a telephone interview, asked the
patient to send us the latest available lung function report,
and supplied them with an activity monitor via postal ser-
vice. Patients who underwent lung transplantation within
the observation period (n = 2) were excluded from this
study. Censor date for mortality analyses was October 4th
2016. Baseline and follow-up visits were performed at least
4 weeks after the latest respiratory tract infection or
exacerbation.
The study was approved by the Ethics Committees of
the Medical Association Schleswig-Holstein (AZ 038/
12 II), and of the University of Heidelberg (S-200/
2013), respectively. All participants provided written in-
formed consent.
Physical activity
We measured physical activity using the same multisensory
armband (SenseWear Pro; BodyMedia Inc., Pittsburgh, PA,
USA) at baseline and at follow-up over a period of 1 week
each, as previously described [20, 22]. The armband is worn
on the upper left arm over the triceps muscle and incorpo-
rates amongst others a triaxial accelerometer that records
average steps per day, which correlate best with dyspnea,
quality of life and lung function in patients with IPF [20].
We instructed patients to wear the armband for 24 h/ day
except for the time spent on personal hygiene. A threshold
of 94% of wearing time (22.5 h) was used to identify valid
days [22].
Lung function and exercise capacity
We performed spirometry (forced vital capacity, FVC;
forced expiratory volume at one second, FEV1) and diffus-
ing capacity for carbon monoxide (DLCO) in line with
current guidelines using established reference values [23,
24]. We measured the 6-min walking distance (6MWD)
according to previous guidelines [25].
Disease severity and disease progression
We assessed disease severity and risk of mortality accord-
ing to the GAP (Gender – Age – Physiology) score and
GAP staging system [8]. We defined stable IPF as FVC
%pred. decline less than 5% [26], and 6MWD decline less
than 30 m [27] according to established values for min-
imal clinically important differences (MCID) in IPF.
Statistical analysis
Descriptive data of survivors and non-survivors are re-
ported as mean and standard deviation (continuous
variables), median and inter-quartile range (categorical
variables and continuous variables with skewed distribu-
tion), or number and percent (dichotomous variables), as
appropriate. Cross-sectional differences were compared
using two-tailed t-test for normally distributed variables,
Mann-Whitney-U test for categorical variables, and χ2
tests for dichotomous variables.
We analyzed the relationship of physical activity and all-
cause mortality by Kaplan-Meier survival plots and log
rank tests using tertiles of steps per day. We compared
these findings to measures of lung function (i.e. FVC
%pred. and DLCO %pred.) and exercise capacity (i.e.
6MWD), and therefore these variables were also classified
according to tertile distribution. We then calculated the
area under the receiver operating characteristic (AUROC)
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curve for the different continuous variables and for the
GAP score, respectively, to discriminate between survi-
vors and non-survivors. The results of AUROC-curve
analyses can be interpreted in analogy to C-statistics. In
a next step, we used multivariate COX regression ana-
lyses to estimate the relative risk of all-cause mortality
associated with the different variables. First, we calcu-
lated the crude hazard ratios for each raw parameter.
Second, we standardized variables for better compar-
ability by dividing continuous variables by one standard
deviation. These standardized variables then were intro-
duced in a multivariate COX regression model that was
also adjusted for sex, age, and antifibrotic therapy as
basic confounders. This second step was not done for
the GAP score that already includes age and sex. In a
final step, we then investigated whether physical activity
had any additional effect on mortality prediction
beyond lung function (i.e. FVC %pred. and DLCO
%pred., respectively).
In survivors, longitudinal differences between mea-
surements at baseline and follow-up were tested by
paired t-test or Wilcoxon rank, as appropriate. Average
annual decline rates among 3-year survivors were cal-
culated by referring the absolute decline rates to a fixed
time interval, i.e. follow-up time in years ((follow-up
value – baseline value)/ years to follow-up). Among pa-
tients with complete baseline and follow-up data for
physical activity, we identified the proportion of pa-
tients with stable disease throughout the observation
period, according to pre-specified decline rates for lung
function and exercise capacity, respectively. Finally, we
compared the amount of physical activity decline
between patients with stable disease and progressive
disease with separate ANOVAs for repeated measures,
respectively.
A p-value <0.05 was considered statistically significant.
Data analysis was performed with the Statistical Package
for Social Science, version 20.0 (SPSS, Chicago, Ill. USA).
Results
We followed 46 patients with IPF over a median time
of 34 [20–38] months. Twenty patients (43%) died
within this observation period. At baseline, non-
survivors had lower lung function, exercise capacity
and physical activity compared to survivors (Table 1).
Furthermore, non-survivors had a higher GAP score
and used antifibrotic therapy less frequently (Table 1).
Frequencies of comorbidities were numerically different
for some disease entities (Table 1). Among survivors,
the type of antifibrotic drug was unchanged throughout
the observation period in 19 patients (73%), and chan-
ged in five patients (19%); in one patient (4%) antifibro-
tic therapy was completely stopped, and in one other
patient (4%) newly initiated.
The probability of surviving the observation period dif-
fered significantly across tertiles of FVC %pred., DLCO
%pred., 6MWD, and steps per day (Fig. 1a-d).
The prognostic values of lung function, exercise cap-
acity, steps per day, and GAP score for mortality predic-
tion are shown in Table 2. Each variable was significantly
associated with an increased risk of death in patients with
IPF (Table 2). Steps per day and FVC %pred. showed the
Table 1 Patient characteristics at baseline by survival status
Characteristic Survivors
(n = 26)
Non-survivors
(n = 20)
p-value
Description
Age, years 65.8 (6.8) 69.2 (8.5) 0.14
Male 18 (69%) 17 (85%) 0.21
BMI, kg/m2 28.2 (4.0) 27.7 (4.9) 0.67
Use of Antifibrotic Therapy 24 (92%) 14 (70%) 0.048
LTOT 5 (20%) 5 (25%) 0.69
pO2 at rest, mmHg 72.1 (8.2) 70.2 (9.7) 0.50
Lung Function
FVC, liter 3.1 (0.8) 2.3 (0.7) 0.002
FVC, %pred. 85.1 (21.4) 64.3 (17.2) 0.001
FEV1 / FVC 0.85 (0.06) 0.81 (0.07) 0.08
DLCO, %pred. 48.7 (13.5) 35.9 (12.9) 0.002
Exercise Capacity
6MWD, meters 415 (128) 299 (118) 0.003
Physical Activity
Steps per day 6606 (3064) 3433 (2655) +0.001
Disease Severity
GAP Score 4 [2–4] 5 [4–5] 0.005
GAP Stage II [I – II] II [II – II] 0.02
Comorbidities
Pulmonary Hypertension 1 (4%) 1 (5%) 0.85
Arterial Hypertension 9 (35%) 10 (50%) 0.29
Cardiovascular Diseasesa 7 (27%) 7 (35%) 0.56
Diabetes Mellitus 1 (4%) 4 (20%) 0.08
GERD 6 (23%) 2 (10%) 0.25
Lung Cancer 0 1 (4%) 0.25
Depression 1 (4%) 0 0.38
Mean number of comorbidities
per patient ≥ 1b
17 (65%) 17 (85%) 0.13
Data are presented as mean (SD), median [IQR] or n (%) depending on scale
and distributional characteristics
Data were missing for LTOT (n = 1) and pO2 (n = 2)
Abbreviations: LTOT long-term oxygen therapy, pO2 partial pressure of oxygen
in capillary blood analysis, FVC forced vital capacity, FEV1 forced expiratory vol-
ume at one second, DLCO diffusing capacity of the lung for carbon monoxide,
6MWD 6-min walking-distance, GAP Gender-Age-Physiology, GERD gastro-
esophageal reflux disease
aCardiovascular diseases encompassed coronary artery disease, left heart
failure or any other cardiovascular diseases, respectively
bN = 9 (35%) and n = 3 (15%) patients had no comorbidities, respectively.
Nobody had ≥4 comorbidities
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best ability (i.e. sensitivity and specificity) to distinguish
between survivors and non-survivors with an AUROC
curve of 0.79 (Table 2; Fig. 2). Adjusting for sex, age and
therapy, and using standardized continuous variables, a
standardized increase (i.e. one SD) in steps per day, FVC
%pred. or DLCO %pred. was associated with a more than
halved risk of death (HR < 0.50; p < 0.01) (Table 2). In
multivariate Cox regression analyses adjusting for age, sex,
and either FVC %pred. or DLCO %pred., steps per day
showed no independent additional effect on mortality pre-
diction (HR 0.99988 [0.99970–1.00007], p = 0.216; HR
0.99989 [0.99970–1.00007], p = 0.225; respectively).
In patients surviving the observation period (n = 26),
valid physical activity data were available in 23 cases at
Fig. 1 Kaplan-Meier survival curves for tertiles of baseline values of forced vital capacity (FVC %pred.) (a), diffusing capacity of the lung for carbon
monoxide (DLCO %pred.) (b), 6-min walking distance (6MWD) (c) and steps per day (d) are displayed on the left. Longitudinal changes (i.e. baseline
and follow-up values of survivors) of FVC %pred. (e), DLCO %pred. (f), 6MWD (g) and steps per day (h) are displayed as bar-charts on the right. In
Kaplan-Meier survival curves solid lines represent the lowest tertile, dashed lines the mid tertile and dotted lines the highest tertile of the baseline values
of FVC %pred. (a), DLCO %pred.(b), 6MWD (c) and steps per day (d), respectively. Censored data of surviving patients are represented as vertical dashes.
P-values are presented within the single graphs. Bar-charts represent baseline (dark grey, left) and follow-up (light grey, right) data of FVC %pred. (e),
DLCO %pred. (f), 6MWD (g) and steps per day (h). Comparissons between baseline and follow-up were made with paired t-tests and p-values were
<0.001, 0.024, 0.055 and <0.001, respectively
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follow-up. In two patients wearing time of the accelerom-
eter did not meet predefined criteria, and one patient re-
fused to repeat the PA measurement at follow-up. Among
survivors with complete follow-up data for physical activ-
ity, lung function and physical activity were significantly
lower at follow-up compared to baseline, while exercise
capacity as measured by 6MWD showed a statistic trend
only (Fig. 1e-h, Table 3). Relative declines between base-
line and follow-up were disproportionally larger for
physical activity compared to lung function and 6MWD
(Table 3). According to pre-specified decline rates for
FVC%pred. and 6MWD (i.e. FVC%pred. <5%, and
6MWD <30 m), 39% (n = 9) and 48% (n = 11) of the pa-
tients with complete data sets were classified as having
stable disease, as longitudinal changes after 3 years were
below the MCID, respectively. Among patients with stable
FVC and 6MWD, physical activity declined by
3213 ± 2203 and 3198 ± 2812 steps per day, respectively.
Patients with progressive disease - as indicated by FVC
and 6MWD decline - showed similar physical activity de-
cline (3033 ± 2594 and 3120 ± 2090 steps per day, respect-
ively; p-values 0.414 and 0.264, respectively).
Discussion
The main finding of our study is that objectively measured
physical activity is a novel predictor of mortality in pa-
tients with IPF. Furthermore, physical activity nearly
halves in IPF patients surviving a follow-up period of
3 years. The ability to predict mortality is similar to estab-
lished measures such as lung function, while physical ac-
tivity decline in survivors is much more pronounced than
suggested by longitudinal changes in lung function or
6MWD only.
Physical activity has just recently been investigated in
patients with IPF in cross-sectional studies, and associa-
tions with lung function, exercise capacity and patient-
reported outcomes have been demonstrated [20, 21, 28,
29]. Our study is the first to present longitudinal data. In
patients with IPF we observed a 48% decline in steps per
day within the observation period of 3 years. Interest-
ingly, after these 3 years with an average annual decline
of nearly 1000 steps per day the total number of steps in
survivors very much resembled the initial number of
steps in patients that didn’t survive this observation
period. Furthermore, the physical activity decline in IPF
seems to be more than twice as high compared to the
changes in patients with severe COPD, in whom a
Table 2 Prognostic value of physical activity and established predictors of mortality in patients with IPF
C statistic Crude Cox regression of the raw predictors Adjusted Cox regression of the standardized predictors
AUROC 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Lung Function
FVC %pred. 0.79 0.65–0.92 0.001 0.96 0.94–0.99 0.001 0.36 0.20–0.66 0.001
DLCO %pred. 0.78 0.64–0.92 0.001 0.94 0.91–0.98 0.002 0.33 0.17–0.67 0.002
Exercise Capacity
6MWD 0.77 0.63–0.91 0.002 0.96a 0.93-0.98 0.003 0.56 0.37–0.87 0.009
Physical Activity
Steps per day 0.79 0.65–0.92 0.001 0.97b 0.96-0.99 0.002 0.46 0.26–0.82 0.008
Disease Severity
GAP Score 0.74 0.59–0.89 0.006 1.63 1.19–2.24 0.003 n/a n/a n/a
Adjustment was done for sex, age and antifibrotic therapy. For standardization, all continuous variables were divided by one standard deviation
Abbreviations: AUROC area under the receiver operating characteristics, HR hazard ratio, CI confidence interval, FVC forced vital capacity, DLCO diffusing capacity of
the lung for carbon monoxide, 6MWD 6-min walking-distance, GAP Gender-Age-Physiology
aCrude HR for 6MWD is reported per 10 m change. Therefore 6MWD results were divided by 10
bCrude HR for SPD is reported per 100 steps change. Therefore SPD results were divided by 100
Fig. 2 Receiver operating characteristic (ROC) curves for the GAP score
and the number of steps per day. The corresponding areas under the
curves (AUROC) were 0.74 and 0.79, respectively
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previous study found average annual decline rates of 435
and 461 steps in COPD patients with GOLD III and IV,
respectively [30].
Compared to the large decline in physical activity in pa-
tients with IPF, decline in exercise capacity was dispropor-
tionally smaller. Generally, those patients that survived
the observation period showed a rather preserved exercise
capacity at baseline and follow-up. However, the observa-
tion period of 3 years is rather long for a study with IPF
patients and coincides with the median survival time [1].
Therefore, the relatively preserved exercise capacity in our
study might be biased by the fact that patients with rapid
6MWD-decline did not survive three years of observation
[10]. For that same reason, the data on 6MWD-decline
from other cohorts with an observation period of twelve
months only, might not be comparable to our 3-year data
with its calculated annual decline [27, 31, 32]. Neverthe-
less, our present study depicts an astonishing discrepancy
between 6MWD and physical activity when studied longi-
tudinally in patients with IPF. This discrepancy suggests
that physical activity and exercise capacity reflect different
aspects of the functional status of IPF patients when the
disease progresses.
FVC currently is the most frequently chosen measure
of disease progression in IPF and standard primary out-
come in clinical studies [2, 3]. In recent phase 3 clinical
trials antifibrotic agents have successfully reduced FVC-
decline and slowed down disease progression, as indi-
cated by the proportion of patients with an FVC-decline
below 10% [2, 3]. However, conclusions with respect to
mortality and the functional status of the patients
remain a matter of debate [2, 3, 13–15]. In our study,
average annual FVC-decline of 130 ml is in line with re-
cent clinical trial results of pirfenidone [2] and ninteda-
nib [3], given the fact that all but two of the surviving
IPF patients received either one of the two treatments.
According to FVC-decline, up to 40% of the surviving
patients would have been evaluated as having stable
disease - even when choosing a more conservative
threshold (i.e. relative FVC-decline <5%) [26]. However,
physical activity decreased in both patients with rela-
tively stable FVC and in those patients with a clinically
meaningful decline in FVC. Interestingly, decline rates
were similar between both groups. These results suggest
that longitudinal measures of FVC might underestimate
clinical deteriorations as indicated by physical activity
decline.
Although numbers are small and only two time points
are available, we believe that our results support further
evaluation of physical activity as an objective measure of
disease progression in IPF. Measures of physical activity
represent a direct objective measure of a patient’s func-
tional status, and when assessed longitudinally they reflect
information beyond currently established surrogates of
disease progression. Complementary assessment of both
physical activity and established clinical variables might
improve adequate prediction of the course of the disease,
as measures of lung function decline alone rather poorly
predicted future disease progression [32].
Previous studies showed a link between activities of
daily living or self-reported daily physical activity and
mortality in patients with IPF [33, 34]. However, ques-
tionnaire data need to be interpreted with care as the
amount of physical activity might be under- or overesti-
mated by the patients [19]. Furthermore, they are subject
to recall bias and require confirmation by objective mea-
surements, especially when studied in smaller patient co-
horts [19]. Objectively measured physical activity and
mortality have also been linked to another in a previous
study by Wallaert et al. in patients with various entities
of fibrotic idiopathic interstitial pneumonia during a
follow-up period ranging from 6 to 36 months [21]. The
various fibrotic entities and wide range of follow-up
makes it difficult to draw firm conclusions for patients
with IPF. Nevertheless, in the study by Wallaert et al.
3300 steps per day were associated with an increased
risk of mortality, which is very similar to the baseline
count of 3400 steps per day in non-surviving IPF pa-
tients in our study [21].
Comparing physical activity to established mortality
predictors, such as lung function we found very similar
prognostic capacity. Furthermore, we saw no independ-
ent contribution of physical inactivity on mortality pre-
diction beyond lung function impairment in this study.
Table 3 Longitudinal changes in lung function, exercise capacity and physical activity in survivors
Characteristic Absolute value
at baseline
Absolute value
at follow-up
Absolute decline
(Baseline to follow-up)
Relative decline
(Baseline to follow-up)
Average annual
decline
p-value
FVC, liter 3.05 (0.81) 2.64 (0.78) −0.41 (0.33) 13.3% −0.13 (0.11) <0.001
FVC, %pred. 84.8 (22.9) 76.1 (23.9) −8.7 (9.6) 10.5% −2.8 (3.0) <0.001
DLCO, %pred. 50.7 (13.6) 43.5 (18.4) −7.3 (13.3) 14.4% −2.2 (4.2) 0.024
6MWD, meters 418 (117) 389 (132) −29 (64) 7.8% −8.8 (20) 0.055
Steps per day 6499 (3192) 3482 (2350) −3017 (2372) 48.3% −973 (743) <0.001
Data are presented as mean (SD) and % for n = 23 survivors with complete physical activity data at follow-up. Differences between baseline and follow-up visit
were tested by paired t-tests. Follow-up data were missing for FVC (n = 1), DLCO (n = 3), and 6MWD (n = 2)
Abbreviations: FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, 6MWD 6-min walking-distance
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By contrast, we showed previously in patients with COPD
that physical activity is the strongest predictor of all-cause
mortality with a substantial prognostic capacity beyond
established predictors like lung function or exercise
capacity [35].
Objective and valid surrogates of mortality in patients
with IPF are an urgent clinical need, as therapeutic trials
studying all-cause mortality in IPF may not be feasible,
due to the necessary size, duration and cost [17]. The
results of our study suggest that objectively measured
daily physical activity might be a valuable surrogate of
mortality in IPF that deserves further evaluation in large
cohorts of IPF patients, and that might possibly also be
considered as complementary outcome measure in clin-
ical trials.
Our study has several limitations. First, the sample size
is relatively small which might lead to either over- or
underestimation of certain effects. Therefore, larger stud-
ies are needed to confirm our findings. Second, survivors
used antifibrotic therapy more frequently and tended to
be younger. As this is an observational study we cannot
exclude that both confounding factors affected our results,
even though we adjusted for these confounders. Third,
there are only two time points available. Application of
average decline rates in longitudinal studies with only two
measurements presumes that the disease course is linear,
which might not be true for IPF [32].
Conclusion
Our data suggest that in patients with IPF objectively mea-
sured daily physical activity might be a valuable assessment
for disease progression and mortality, respectively. Current
measures of disease progression might not adequately re-
flect the impact of clinical worsening of the disease on the
patient’s everyday life.
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